Azura Ophthalmics Ltd, an Israeli developer of therapies for Meibomian gland dysfunction and related eye diseases, has raised $20 million in financing. The investors included OrbiMed, TPG Biotech, Brandon Capital’s Medical Research Commercialization Fund and Ganot Capital.
Source: Press Release
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: